Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
Total Valuation
Rein Therapeutics has a market cap or net worth of $34.17M. The enterprise value is $30.12M.
Market Cap$34.17M
Enterprise Value$30.12M
Share Statistics
Rein Therapeutics has 26,286,383 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,286,383
Owned by Insiders7.15%
Owned by Institutions0.22%
Financial Efficiency
Rein Therapeutics’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -100.09%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-0.91
Return on Invested Capital (ROIC)-100.09%
Return on Capital Employed (ROCE)-1.03
Revenue Per Employee0.00
Profits Per Employee-5.72M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rein Therapeutics is ―. Rein Therapeutics’s PEG ratio is -0.00025.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-1.64
PEG Ratio-0.00025
Income Statement
In the last 12 months, Rein Therapeutics had revenue of 0.00 and earned -62.88M in profits. Earnings per share was -3.51.
Revenue0.00
Gross Profit0.00
Operating Income-65.11M
Pretax Income-64.31M
Net Income-62.88M
EBITDA-28.05M
Earnings Per Share (EPS)-3.51
Cash Flow
In the last 12 months, operating cash flow was -20.95M and capital expenditures 0.00, giving a free cash flow of -20.95M billion.
Operating Cash Flow-20.95M
Free Cash Flow-20.95M
Free Cash Flow per Share-0.80
Dividends & Yields
Rein Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-32.29%
50-Day Moving Average1.34
200-Day Moving Average1.45
Relative Strength Index (RSI)48.44
Average Volume (3m)228.95K
Important Dates
Rein Therapeutics upcoming earnings date is Apr 6, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateApr 6, 2026
Ex-Dividend Date―
Financial Position
Rein Therapeutics as a current ratio of 2.38, with Debt / Equity ratio of 0.00%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rein Therapeutics has paid -1.54M in taxes.
Income Tax-1.54M
Effective Tax Rate0.02
Enterprise Valuation
Rein Therapeutics EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.58.
EV to Sales0.00
EV to EBITDA0.46
EV to Free Cash Flow0.58
EV to Operating Cash Flow0.58
Balance Sheet
Rein Therapeutics has $4.05M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.05M billion.
Cash & Marketable Securities$4.05M
Total Debt$0.00
Net Cash$4.05M
Net Cash Per Share$0.15
Tangible Book Value Per Share$326.79
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rein Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside693.65% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast15.35%